A Method for Measurement of 3-Bromotyrosine Concentrations in Canine Serum and Its Clinical Application
Abstract
The eosinophil count in the peripheral blood does not accurately represent eosinophil activation in tissues, as eosinophils primarily reside in tissues and not in peripheral blood. To date, a non-invasive biomarker for eosinophil activation in dogs has not yet been described. Therefore, the aims of this study were to (1) develop and analytically validate an electron ionization gas chromatography/mass spectrometry (EI-GC/MS) method to identify and measure 3-Bromotyrosine (3-BrY) concentrations in canine serum, (2) establish a reference interval for serum 3-BrY concentrations in healthy pet dogs, (3) determine the short-term stability of canine serum 3-BrY concentrations, and (4) evaluate the clinical usefulness of measuring 3-BrY concentrations in canine serum.\n\nLeft-over serum samples from dogs were used to analytically validate the assay. Serum samples from 41 healthy dogs were used to establish a reference interval. A stable isotope of 3-BrY, D3-bromotyrosine, was produced in house and added to canine serum samples. 3-BrY in serum samples was extracted and detected by solid-phase extraction and EI-GC/MS, respectively. Limit of blank and limit of detection were 0.33 and 0.63 μmol/L, respectively. Coefficients of variation for precision and reproducibility of the 3-BrY concentrations were <13.9% and <11.0%, respectively. Linearity and accuracy recoveries ranged from 84.0% to 134.4% and 79.1% to 126.7%, respectively. The reference interval was determined to be ≤1.12 μmol/L.…
How strong is the evidence?
Evidence Hub reads this as a thesis, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.